This HTML5 document contains 177 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34614776
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ vitenskapelig artikkel 2009年の論文 article científic artigo científico (publicado na 2009) научни чланак 2009年論文 2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած vedecký článok vitskapeleg artikkel wetenschappelijk artikel 2009年論文 บทความทางวิทยาศาสตร์ mokslinis straipsnis 2009年论文 2009年论文 научная статья tudományos cikk 2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված artikulong pang-agham 2009年論文 vědecký článek 2009년 논문 სამეცნიერო სტატია bilimsel makale наукова стаття, опублікована в грудні 2009 article scientific artykuł naukowy سائنسی مضمون 2009年论文 articolo scientifico 2009年論文 videnskabelig artikel (udgivet 2009) artículu científicu espublizáu en 2009 artigo científico scientific article articol științific 2009年论文 ২০০৯-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ naučni članak artigo científico (publicado na 2009) tieteellinen artikkeli scienca artikolo 2009年論文 teaduslik artikkel wissenschaftlicher Artikel bài báo khoa học 2009年论文 научни чланак מאמר מדעי научна статия artikull shkencor artículo científico publicado en 2009 مقالة علمية article scientifique (publié 2009) 2009 nî lūn-bûn επιστημονικό άρθρο vetenskaplig artikel мақолаи илмӣ مقالهٔ علمی 2009年论文
p:P577
wds:Q34614776-8019739C-CE61-4B54-867B-FFE451616450
wdt:P577
2009-12-08T00:00:00Z
p:P407
wds:Q34614776-E656233E-EBAA-41B6-BBCD-E2B886E39B66
wdt:P407
wd:Q1860
p:P2860
wds:Q34614776-AF27BCA9-E9E1-4C3A-9342-F3D5073810D1 wds:Q34614776-7A416BB8-E3BC-40AF-81B3-7C7C14D5ABC4 wds:Q34614776-803EC004-ADC4-4710-B79E-06E320324D5D wds:Q34614776-868712CA-CD71-4A76-ADB9-80D492327E2F wds:Q34614776-8779FDFE-3F04-4A57-B768-3262618A733E wds:Q34614776-8C6E9D44-E3A2-4485-B01D-B4EE56296B45 wds:Q34614776-ED9BB8F3-4F0D-49A7-ADF1-6A07BD6C9DBB wds:Q34614776-F782F4E2-140C-42C9-AE9C-D98215B5D3DC wds:Q34614776-FD2A6E87-C9DF-489D-B603-C9E4442B5113 wds:Q34614776-BB76FD16-D6C8-4B1B-9E74-488B6B77C10E wds:Q34614776-C3CCDDB0-34D0-4831-A670-A8DEC30EBC3F wds:Q34614776-08D45632-9ED5-40EC-B749-BD07136351D2 wds:Q34614776-19B14267-EAF3-42B5-B0DD-803B6ADFE8E5 wds:Q34614776-6F1EE280-B4A0-4D14-98E9-4AADFFCC35C5 wds:Q34614776-2577591F-6571-4AD2-B21D-F4EE80CB3CA9 wds:Q34614776-3027ADC7-21DD-4BA3-9542-096D3D8D4DD3 wds:Q34614776-32B4701A-E763-4D95-86CE-A9B5AB19398B wds:Q34614776-3986C319-780C-4682-81B2-E7D0F36A062C wds:Q34614776-A6A56097-8D10-40F1-AB9B-55E9435414ED wds:Q34614776-A77699F3-76D0-49D6-A9AA-74B927F12233 wds:Q34614776-ACBEA25B-410A-49FB-9CA9-1075FAB4E94A
wdt:P2860
wd:Q36301801 wd:Q24679736 wd:Q36909389 wd:Q33372613 wd:Q30048279 wd:Q36389992 wd:Q35877006 wd:Q29619885 wd:Q36286133 wd:Q46087025 wd:Q38502534 wd:Q34959906 wd:Q24246409 wd:Q28265610 wd:Q37387037 wd:Q36365463 wd:Q37288227 wd:Q34657668 wd:Q28275730 wd:Q43293811 wd:Q37000638
p:P2093
wds:Q34614776-78E30BAD-7B4B-4B79-BD31-43FC82FA29D6 wds:Q34614776-66D9E584-C400-43BB-82A3-F70E28442819 wds:Q34614776-5E84CA79-A647-4655-86DE-50A0B702E022 wds:Q34614776-1BC44B53-1EED-4736-93D6-EE2FE35278D5 wds:Q34614776-1A24527E-5D04-42AE-B9B9-73003D2FF85D wds:Q34614776-1B9AB300-4A3D-4F47-9322-EDD3C1BFFC75 wds:Q34614776-19D44393-1535-4F1C-8780-D666DDC73397 wds:Q34614776-14ED5ED3-BCD4-4761-84C3-39A0906C7AF5 wds:Q34614776-062266BF-01CA-4A27-9B2F-06B7A8E565B2 wds:Q34614776-E0A4DD47-A7B5-4593-AE33-C015FA8E2D65 wds:Q34614776-E3B56211-80C6-4428-BAEC-A99D0292A3F3 wds:Q34614776-D2326F6C-62A8-4522-9AD2-EE3759A26C94 wds:Q34614776-93C656E3-C577-4A3A-877C-B2AD69B92004 wds:Q34614776-9961CBD2-472A-4654-B1A4-E1DEB9735049 wds:Q34614776-9340FDC6-71C7-4F6C-8355-E46F3E688C20
wdt:P2093
Luc Thomas Kevin Chin Gerald Linette Jean-Jacques Grob Jason Chesney Bart Neyns Troy Guthrie Axel Hoos Steven J O'Day William Waterfield Kun Chen Sylvie Negrier Jose Lutzky Michael Smylie Celeste Lebbé
rdfs:label
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
skos:prefLabel
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
schema:name
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
p:P50
wds:Q34614776-B4962DC6-3FD8-4F00-8267-F1AA60AC093E wds:Q34614776-9BA5B46E-9A0F-4411-AFBE-C797052D2E00 wds:Q34614776-9CABF34C-DCAA-4512-B3DA-5EAFA3435819
wdt:P50
wd:Q32649390 wd:Q40580858 wd:Q88137705
p:P1476
wds:Q34614776-5C5FC74A-E830-4EB5-AFD4-A9694ADEC03B
wdt:P1476
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
p:P304
wds:Q34614776-B9DC4311-40FB-4C11-85CF-F559121C8A97
wdt:P304
155-164
p:P31
wds:Q34614776-B754DDE5-175A-4C61-9B16-65A3AB3F0515
wdt:P31
wd:Q13442814
p:P921
wds:Q34614776-79CAB571-EB4B-4254-8B42-66191FCDFB2E wds:Q34614776-BECA507E-4BC1-41F0-8932-17241B57CE44
wdt:P921
wd:Q6934595 wd:Q2459042
p:P698
wds:Q34614776-727FE6CB-D2D8-46BA-B1B2-EB410EC516B9
wdtn:P698
n11:20004617
wdt:P698
20004617
p:P1433
wds:Q34614776-C503C036-1159-44E9-9BC9-150F1BB8A801
wdt:P1433
wd:Q13747613
p:P433
wds:Q34614776-66296F8B-F1BD-438D-9F7C-B55EB9F18DAE
p:P478
wds:Q34614776-3D3F84BB-5CA3-4440-A261-231D298E8286
wdt:P433
2
wdt:P478
11
p:P356
wds:Q34614776-265D5DEC-C04D-4E0B-91D2-F8B4104FC486
wdtn:P356
n12:S1470-2045(09)70334-1
wdt:P356
10.1016/S1470-2045(09)70334-1
p:P5875
wds:Q34614776-0DB3CB28-80B7-4380-BA6E-596CA9B68680
wdt:P5875
40682461